There are widespread speculations that Ibio Inc (NYSEMKT:IBIO) could be a partner in the production of ZMapp. The investigation drug was developed by MAP Pharmaceuticals Inc. (NASDAQ:MAPP) and it was used in the treatment of the two U.S. health workers who had contracted Ebola virus during their service in Africa. The two Americans with Ebola recovered from Ebola. Ibio Inc (NYSEMKT:IBIO) is an early-stage pharmaceutical company whose technology can help in the commercial production of ZMapp as fears over Ebola deepen with more deaths and infections being reported. A nurse that administered treatment to the Liberian man with Ebola in Dallas had contracted the virus. Even in Spain, a nurse who attended to an Ebola victim was also reported to have contracted the disease. Meanwhile, Ebola continues to wreck havoc in West African where nearly 4,000 people have died of the disease and about 8,000 others infected. The U.S. government is trying to contain the spread of Ebola virus by boosting the production of ZMapp and IBIO could be an important partner in increase the production of the drug.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) released positive mid-stage clinical data from the ongoing study of patisiran, which is a type of gene-silencing drug. The development of such drugs is closely-watch because of the promise they hold in dealing with diseases that currently have no cure. Patisiran is being developed for the treatment of familial amyloid polyneuropathy (FAP), and it showed encouraging results after six months of use in patients. Meanwhile, an insider at Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) recently moved to reduce exposure to the company’s equity. Kevin P. Starr, a Board member of the company, sold 90,000 shares at an average price of $78.09 apiece and generated $7,028,100 in proceeds, according SEC filing. Shares of ALNY are up almost 35% YTD.
Heat Biologics Inc (NASDAQ:HTBX) was affirmed as a “buy” at Aegis Capital. The firm also set $22 price target on the stock. The affirmation of a positive rating on the stock of Heat Biologics (HTBX) followed the news about the dosing of the final patient in the Phase 1/2 trial for Vesigenurtacel-L (HS-410). HTBX is developing the treatment for combating bladder cancer.